UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015
Operating revenue:
Personalized oncology solutions	$ 416	$ 453	$ 1,387	$ 1,245
Translational oncology solutions	2,136	1,376	6,958	4,377
Total operating revenue	2,552	1,829	8,345	5,622
Costs and operating expenses:
Cost of personalized oncology solutions	479	674	1,661	2,190
Cost of translational oncology solutions	1,627	1,301	4,683	3,225
Research and development	999	1,093	3,018	3,757
Sales and marketing	779	1,094	2,688	3,340
General and administrative	1,041	1,086	4,062	3,944
Total costs and operating expenses	4,925	5,248	16,112	16,456
Loss from operations	(2,373)	(3,419)	(7,767)	(10,834)
Other (expense) income:
Change in fair value of warrant liability	0	621	0	1,401
Other (expense)	(8)	(6)	(29)	(3)
Total other (expense) income	(8)	615	(29)	1,398
Loss before provision for income taxes	(2,381)	(2,804)	(7,796)	(9,436)
Provision for income taxes	31	12	76	27
Net loss	$ (2,412)	$ (2,816)	$ (7,872)	$ (9,463)
Net loss per common share outstanding
basic (in dollars per share)	$ (0.28)	$ (0.51)	$ (0.90)	$ (1.70)
diluted (in dollars per share)	$ (0.28)	$ (0.61)	$ (0.90)	$ (1.94)
Weighted average common shares outstanding
basic (in shares)	8,702,237	5,574,447	8,702,237	5,574,244
diluted (in shares)	8,702,237	5,603,798	8,702,237	5,603,595